APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Cyproheptadine

Compare research editions
View pricing & licenses

Selected research

Industry Research

Cyproheptadine Industry Research Report 2026

Report ID 173982010519 December 2025143 pages

Choose your research edition.

Industry ResearchCyproheptadine Industry Research Report 2026143 pages · $2,950 USDIndustry Growth & TrendsGlobal Cyproheptadine Industry Growth and Trends Forecast to 2032120 pages · $3,450 USDMarket StructureGlobal Cyproheptadine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Cyproheptadine Market Outlook and Growth Opportunities 2026215 pages · $4,250 USDMarket Analysis & ForecastGlobal Cyproheptadine Market Analysis and Forecast 2026-2032212 pages · $4,950 USD

Market perspective

The global Cyproheptadine market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.

The North America market for Cyproheptadine is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.

The Europe market for Cyproheptadine is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.

Read the full market overview

The Asia Pacific market for Cyproheptadine is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.

Leading global manufacturers of Cyproheptadine include MSD, Abbott, Teva, Novartis, Teriak, Royal Pharma, Qualipharm, Pharma Arte and Panbiotic Laboratories, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report quantifies the global Cyproheptadine market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).

The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.

Key Companies & Market Share Insights

This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

Cyproheptadine Market by Company

MSD

Abbott

Teva

Novartis

Teriak

Royal Pharma

Qualipharm

Pharma Arte

Panbiotic Laboratories

Nichi-Iko Pharmaceutical

Medphano

Laboratoires Servier

Kalbe

General Pharma

Fu Yuan Pharmaceutical

Faes Pharma

Cipla Medpro South Africa

Caillon and Hamonet

Arena Pharmaceuticals

Apex Pharma

Allena Pharmaceuticals

Aero-Chem

Cyproheptadine Segment by Type

Patent

Generic

Cyproheptadine Segment by Application

On-line

Drug Store

Hospital

Cyproheptadine Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Cyproheptadine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Cyproheptadine and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Cyproheptadine.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Detailed analysis of Cyproheptadine manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.

Chapter 5: Production/output, value of Cyproheptadine by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.

Chapter 6: Consumption of Cyproheptadine in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.

Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 11: The main points and conclusions of the report.

More report detail

Tables and figures
List of Tables Table 1. Secondary Sources Table 2. Primary Sources Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Cyproheptadine Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025) Table 6. Global Cyproheptadine Sales (K Units) of Manufacturers (2021-2026) Table 7. Global Cyproheptadine Sales Market Share by Manufacturers (2021-2026) Table 8. Global Cyproheptadine Revenue of Manufacturers (2021-2026) Table 9. Global Cyproheptadine Revenue Share by Manufacturers (2021-2026) Table 10. Global Market Cyproheptadine Average Price (US$/Unit) of Manufacturers (2021-2026) Table 11. Global Cyproheptadine Industry Ranking, 2024 VS 2025 VS 2026 Table 12. Global Manufacturers of Cyproheptadine, Manufacturing Sites & Headquarters Table 13. Global Manufacturers of Cyproheptadine, Product Type & Application Table 14. Global Cyproheptadine Manufacturers Established Date Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 16. Global Cyproheptadine by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans) Table 18. MSD Company Information Table 19. MSD Business Overview Table 20. MSD Cyproheptadine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 21. MSD Cyproheptadine Product Portfolio Table 22. MSD Recent Developments Table 23. Abbott Company Information Table 24. Abbott Business Overview Table 25. Abbott Cyproheptadine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 26. Abbott Cyproheptadine Product Portfolio Table 27. Abbott Recent Developments Table 28. Teva Company Information Table 29. Teva Business Overview Table 30. Teva Cyproheptadine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 31. Teva Cyproheptadine Product Portfolio Table 32. Teva Recent Developments Table 33. Novartis Company Information Table 34. Novartis Business Overview Table 35. Novartis Cyproheptadine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 36. Novartis Cyproheptadine Product Portfolio Table 37. Novartis Recent Developments Table 38. Teriak Company Information Table 39. Teriak Business Overview Table 40. Teriak Cyproheptadine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 41. Teriak Cyproheptadine Product Portfolio Table 42. Teriak Recent Developments Table 43. Royal Pharma Company Information Table 44. Royal Pharma Business Overview Table 45. Royal Pharma Cyproheptadine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 46. Royal Pharma Cyproheptadine Product Portfolio Table 47. Royal Pharma Recent Developments Table 48. Qualipharm Company Information Table 49. Qualipharm Business Overview Table 50. Qualipharm Cyproheptadine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 51. Qualipharm Cyproheptadine Product Portfolio Table 52. Qualipharm Recent Developments Table 53. Pharma Arte Company Information Table 54. Pharma Arte Business Overview Table 55. Pharma Arte Cyproheptadine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 56. Pharma Arte Cyproheptadine Product Portfolio Table 57. Pharma Arte Recent Developments Table 58. Panbiotic Laboratories Company Information Table 59. Panbiotic Laboratories Business Overview Table 60. Panbiotic Laboratories Cyproheptadine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 61. Panbiotic Laboratories Cyproheptadine Product Portfolio Table 62. Panbiotic Laboratories Recent Developments Table 63. Nichi-Iko Pharmaceutical Company Information Table 64. Nichi-Iko Pharmaceutical Business Overview Table 65. Nichi-Iko Pharmaceutical Cyproheptadine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 66. Nichi-Iko Pharmaceutical Cyproheptadine Product Portfolio Table 67. Nichi-Iko Pharmaceutical Recent Developments Table 68. Medphano Company Information Table 69. Medphano Business Overview Table 70. Medphano Cyproheptadine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 71. Medphano Cyproheptadine Product Portfolio Table 72. Medphano Recent Developments Table 73. Laboratoires Servier Company Information Table 74. Laboratoires Servier Business Overview Table 75. Laboratoires Servier Cyproheptadine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 76. Laboratoires Servier Cyproheptadine Product Portfolio Table 77. Laboratoires Servier Recent Developments Table 78. Kalbe Company Information Table 79. Kalbe Business Overview Table 80. Kalbe Cyproheptadine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 81. Kalbe Cyproheptadine Product Portfolio Table 82. Kalbe Recent Developments Table 83. General Pharma Company Information Table 84. General Pharma Business Overview Table 85. General Pharma Cyproheptadine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 86. General Pharma Cyproheptadine Product Portfolio Table 87. General Pharma Recent Developments Table 88. Fu Yuan Pharmaceutical Company Information Table 89. Fu Yuan Pharmaceutical Business Overview Table 90. Fu Yuan Pharmaceutical Cyproheptadine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 91. Fu Yuan Pharmaceutical Cyproheptadine Product Portfolio Table 92. Fu Yuan Pharmaceutical Recent Developments Table 93. Faes Pharma Company Information Table 94. Faes Pharma Business Overview Table 95. Faes Pharma Cyproheptadine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 96. Faes Pharma Cyproheptadine Product Portfolio Table 97. Faes Pharma Recent Developments Table 98. Cipla Medpro South Africa Company Information Table 99. Cipla Medpro South Africa Business Overview Table 100. Cipla Medpro South Africa Cyproheptadine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 101. Cipla Medpro South Africa Cyproheptadine Product Portfolio Table 102. Cipla Medpro South Africa Recent Developments Table 103. Caillon and Hamonet Company Information Table 104. Caillon and Hamonet Business Overview Table 105. Caillon and Hamonet Cyproheptadine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 106. Caillon and Hamonet Cyproheptadine Product Portfolio Table 107. Caillon and Hamonet Recent Developments Table 108. Arena Pharmaceuticals Company Information Table 109. Arena Pharmaceuticals Business Overview Table 110. Arena Pharmaceuticals Cyproheptadine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 111. Arena Pharmaceuticals Cyproheptadine Product Portfolio Table 112. Arena Pharmaceuticals Recent Developments Table 113. Apex Pharma Company Information Table 114. Apex Pharma Business Overview Table 115. Apex Pharma Cyproheptadine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 116. Apex Pharma Cyproheptadine Product Portfolio Table 117. Apex Pharma Recent Developments Table 118. Allena Pharmaceuticals Company Information Table 119. Allena Pharmaceuticals Business Overview Table 120. Allena Pharmaceuticals Cyproheptadine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 121. Allena Pharmaceuticals Cyproheptadine Product Portfolio Table 122. Allena Pharmaceuticals Recent Developments Table 123. Aero-Chem Company Information Table 124. Aero-Chem Business Overview Table 125. Aero-Chem Cyproheptadine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 126. Aero-Chem Cyproheptadine Product Portfolio Table 127. Aero-Chem Recent Developments Table 128. Global Cyproheptadine Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Table 129. Global Cyproheptadine Sales by Region (2021-2026) & (K Units) Table 130. Global Cyproheptadine Sales Market Share by Region (2021-2026) Table 131. Global Cyproheptadine Sales by Region (2027-2032) & (K Units) Table 132. Global Cyproheptadine Sales Market Share by Region (2027-2032) Table 133. Global Cyproheptadine Revenue by Region (2021-2026) & (US$ Million) Table 134. Global Cyproheptadine Revenue Market Share by Region (2021-2026) Table 135. Global Cyproheptadine Revenue by Region (2027-2032) & (US$ Million) Table 136. Global Cyproheptadine Revenue Market Share by Region (2027-2032) Table 137. North America Cyproheptadine Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 138. North America Cyproheptadine Sales by Country (2021-2026) & (K Units) Table 139. North America Cyproheptadine Sales by Country (2027-2032) & (K Units) Table 140. North America Cyproheptadine Revenue by Country (2021-2026) & (US$ Million) Table 141. North America Cyproheptadine Revenue by Country (2027-2032) & (US$ Million) Table 142. Europe Cyproheptadine Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 143. Europe Cyproheptadine Sales by Country (2021-2026) & (K Units) Table 144. Europe Cyproheptadine Sales by Country (2027-2032) & (K Units) Table 145. Europe Cyproheptadine Revenue by Country (2021-2026) & (US$ Million) Table 146. Europe Cyproheptadine Revenue by Country (2027-2032) & (US$ Million) Table 147. Asia Pacific Cyproheptadine Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 148. Asia Pacific Cyproheptadine Sales by Country (2021-2026) & (K Units) Table 149. Asia Pacific Cyproheptadine Sales by Country (2027-2032) & (K Units) Table 150. Asia Pacific Cyproheptadine Revenue by Country (2021-2026) & (US$ Million) Table 151. Asia Pacific Cyproheptadine Revenue by Country (2027-2032) & (US$ Million) Table 152. South America Cyproheptadine Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 153. South America Cyproheptadine Sales by Country (2021-2026) & (K Units) Table 154. South America Cyproheptadine Sales by Country (2027-2032) & (K Units) Table 155. South America Cyproheptadine Revenue by Country (2021-2026) & (US$ Million) Table 156. South America Cyproheptadine Revenue by Country (2027-2032) & (US$ Million) Table 157. Middle East and Africa Cyproheptadine Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 158. Middle East and Africa Cyproheptadine Sales by Country (2021-2026) & (K Units) Table 159. Middle East and Africa Cyproheptadine Sales by Country (2027-2032) & (K Units) Table 160. Middle East and Africa Cyproheptadine Revenue by Country (2021-2026) & (US$ Million) Table 161. Middle East and Africa Cyproheptadine Revenue by Country (2027-2032) & (US$ Million) Table 162. Global Cyproheptadine Sales by Type (2021-2026) & (K Units) Table 163. Global Cyproheptadine Sales by Type (2027-2032) & (K Units) Table 164. Global Cyproheptadine Sales Market Share by Type (2021-2026) Table 165. Global Cyproheptadine Sales Market Share by Type (2027-2032) Table 166. Global Cyproheptadine Revenue by Type (2021-2026) & (US$ Million) Table 167. Global Cyproheptadine Revenue by Type (2027-2032) & (US$ Million) Table 168. Global Cyproheptadine Revenue Market Share by Type (2021-2026) Table 169. Global Cyproheptadine Revenue Market Share by Type (2027-2032) Table 170. Global Cyproheptadine Price by Type (2021-2026) & (US$/Unit) Table 171. Global Cyproheptadine Price by Type (2027-2032) & (US$/Unit) Table 172. Global Cyproheptadine Sales by Application (2021-2026) & (K Units) Table 173. Global Cyproheptadine Sales by Application (2027-2032) & (K Units) Table 174. Global Cyproheptadine Sales Market Share by Application (2021-2026) Table 175. Global Cyproheptadine Sales Market Share by Application (2027-2032) Table 176. Global Cyproheptadine Revenue by Application (2021-2026) & (US$ Million) Table 177. Global Cyproheptadine Revenue by Application (2027-2032) & (US$ Million) Table 178. Global Cyproheptadine Revenue Market Share by Application (2021-2026) Table 179. Global Cyproheptadine Revenue Market Share by Application (2027-2032) Table 180. Global Cyproheptadine Price by Application (2021-2026) & (US$/Unit) Table 181. Global Cyproheptadine Price by Application (2027-2032) & (US$/Unit) Table 182. Key Raw Materials Table 183. Raw Materials Key Suppliers Table 184. Cyproheptadine Distributors List Table 185. Cyproheptadine Customers List Table 186. Cyproheptadine Industry Trends Table 187. Cyproheptadine Industry Drivers Table 188. Cyproheptadine Industry Restraints Table 189. Authors List of This Report List of Figures Figure 1. Research Methodology Figure 2. Research Process Figure 3. Key Executives Interviewed Figure 4. Cyproheptadine Product Image Figure 5. Global Cyproheptadine Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 6. Global Cyproheptadine Market Size (2021-2032) & (US$ Million) Figure 7. Global Cyproheptadine Sales (2021-2032) & (K Units) Figure 8. Global Cyproheptadine Average Price (US$/Unit) & (2021-2032) Figure 9. Patent Product Image Figure 10. Generic Product Image Figure 11. On-line Product Image Figure 12. Drug Store Product Image Figure 13. Hospital Product Image Figure 14. Global Cyproheptadine Revenue Share by Manufacturers in 2025 Figure 15. Global Manufacturers of Cyproheptadine, Manufacturing Sites & Headquarters Figure 16. Global Top 5 and 10 Cyproheptadine Players Market Share by Revenue in 2025 Figure 17. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 18. Global Cyproheptadine Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Figure 19. Global Cyproheptadine Sales by Region in 2025 Figure 20. Global Cyproheptadine Revenue by Region in 2025 Figure 21. North America Cyproheptadine Market Size by Country in 2025 Figure 22. North America Cyproheptadine Sales Market Share by Country (2021-2032) Figure 23. North America Cyproheptadine Revenue Market Share by Country (2021-2032) Figure 24. United States Cyproheptadine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 25. Canada Cyproheptadine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 26. Europe Cyproheptadine Market Size by Country in 2025 Figure 27. Europe Cyproheptadine Sales Market Share by Country (2021-2032) Figure 28. Europe Cyproheptadine Revenue Market Share by Country (2021-2032) Figure 29. Germany Cyproheptadine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 30. France Cyproheptadine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 31. U.K. Cyproheptadine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 32. Italy Cyproheptadine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 33. Netherlands Cyproheptadine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 34. Asia Pacific Cyproheptadine Market Size by Country in 2025 Figure 35. Asia Pacific Cyproheptadine Sales Market Share by Country (2021-2032) Figure 36. Asia Pacific Cyproheptadine Revenue Market Share by Country (2021-2032) Figure 37. China Cyproheptadine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 38. Japan Cyproheptadine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 39. South Korea Cyproheptadine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 40. India Cyproheptadine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 41. Australia Cyproheptadine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 42. China Taiwan Cyproheptadine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 43. Southeast Asia Cyproheptadine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 44. Southeast Asia Cyproheptadine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 45. South America Cyproheptadine Market Size by Country in 2025 Figure 46. South America Cyproheptadine Sales Market Share by Country (2021-2032) Figure 47. South America Cyproheptadine Revenue Market Share by Country (2021-2032) Figure 48. Mexico Cyproheptadine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 49. Brazil Cyproheptadine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 50. Argentina Cyproheptadine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 51. Middle East and Africa Cyproheptadine Market Size by Country in 2025 Figure 52. Middle East and Africa Cyproheptadine Sales Market Share by Country (2021-2032) Figure 53. Middle East and Africa Cyproheptadine Revenue Market Share by Country (2021-2032) Figure 54. Turkey Cyproheptadine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 55. Saudi Arabia Cyproheptadine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 56. UAE Cyproheptadine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 57. Global Cyproheptadine Sales Market Share by Type (2021-2032) Figure 58. Global Cyproheptadine Revenue Market Share by Type (2021-2032) Figure 59. Global Cyproheptadine Price (US$/Unit) by Type (2021-2032) Figure 60. Global Cyproheptadine Sales Market Share by Application (2021-2032) Figure 61. Global Cyproheptadine Revenue Market Share by Application (2021-2032) Figure 62. Global Cyproheptadine Price (US$/Unit) by Application (2021-2032) Figure 63. Cyproheptadine Value Chain Figure 64. Cyproheptadine Production Mode & Process Figure 65. Direct Comparison with Distribution Share Figure 66. Distributors Profiles Figure 67. Cyproheptadine Industry Opportunities and Challenges

Scope & coverage.

Types
  • Patent
  • Generic
Applications
  • On-line
  • Drug Store
  • Hospital
Companies covered
  • MSD
  • Abbott
  • Teva
  • Novartis
  • Teriak
  • Royal Pharma
  • Qualipharm
  • Pharma Arte
  • Panbiotic Laboratories
  • Nichi-Iko Pharmaceutical
  • Medphano
  • Laboratoires Servier
  • Kalbe
  • General Pharma
  • Fu Yuan Pharmaceutical
  • Faes Pharma
  • Cipla Medpro South Africa
  • Caillon and Hamonet
  • Arena Pharmaceuticals
  • Apex Pharma
  • Allena Pharmaceuticals
  • Aero-Chem

Inside the report.

1 Preface
  1. 1.1 Scope of Report
  2. 1.2 Reasons for Doing This Study
  3. 1.3 Research Methodology
  4. 1.4 Research Process
  5. 1.5 Data Source
  6. 1.5.1 Secondary Sources
  7. 1.5.2 Primary Sources
2 Market Overview
  1. 2.1 Product Definition
  2. 2.2 Global Market Growth Prospects
  3. 2.2.1 Global Cyproheptadine Market Size (2021-2032)
  4. 2.2.2 Global Cyproheptadine Sales (2021-2032)
  5. 2.2.3 Global Cyproheptadine Market Average Price (2021-2032)
  6. 2.3 Cyproheptadine by Type
  7. 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
  8. 2.3.2 Patent
  9. 2.3.3 Generic
  10. 2.4 Cyproheptadine by Application
  11. 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
  12. 2.4.2 On-line
  13. 2.4.3 Drug Store
  14. 2.4.4 Hospital
3 Market Competitive Landscape by Manufacturers
  1. 3.1 Global Cyproheptadine Market Competitive Situation by Manufacturers (2021 Versus 2025)
  2. 3.2 Global Cyproheptadine Sales (K Units) of Manufacturers (2021-2026)
  3. 3.3 Global Cyproheptadine Revenue of Manufacturers (2021-2026)
  4. 3.4 Global Cyproheptadine Average Price by Manufacturers (2021-2026)
  5. 3.5 Global Cyproheptadine Industry Ranking, 2024 VS 2025 VS 2026
  6. 3.6 Global Manufacturers of Cyproheptadine, Manufacturing Sites & Headquarters
  7. 3.7 Global Manufacturers of Cyproheptadine, Product Type & Application
  8. 3.8 Global Manufacturers of Cyproheptadine, Established Date
  9. 3.9 Global Cyproheptadine Market CR5 and HHI
  10. 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
  1. 4.1 MSD
  2. 4.1.1 MSD Company Information
  3. 4.1.2 MSD Business Overview
  4. 4.1.3 MSD Cyproheptadine Sales, Revenue and Gross Margin (2021-2026)
  5. 4.1.4 MSD Cyproheptadine Product Portfolio
  6. 4.1.5 MSD Recent Developments
  7. 4.2 Abbott
  8. 4.2.1 Abbott Company Information
  9. 4.2.2 Abbott Business Overview
  10. 4.2.3 Abbott Cyproheptadine Sales, Revenue and Gross Margin (2021-2026)
  11. 4.2.4 Abbott Cyproheptadine Product Portfolio
  12. 4.2.5 Abbott Recent Developments
  13. 4.3 Teva
  14. 4.3.1 Teva Company Information
  15. 4.3.2 Teva Business Overview
  16. 4.3.3 Teva Cyproheptadine Sales, Revenue and Gross Margin (2021-2026)
  17. 4.3.4 Teva Cyproheptadine Product Portfolio
  18. 4.3.5 Teva Recent Developments
  19. 4.4 Novartis
  20. 4.4.1 Novartis Company Information
  21. 4.4.2 Novartis Business Overview
  22. 4.4.3 Novartis Cyproheptadine Sales, Revenue and Gross Margin (2021-2026)
  23. 4.4.4 Novartis Cyproheptadine Product Portfolio
  24. 4.4.5 Novartis Recent Developments
  25. 4.5 Teriak
  26. 4.5.1 Teriak Company Information
  27. 4.5.2 Teriak Business Overview
  28. 4.5.3 Teriak Cyproheptadine Sales, Revenue and Gross Margin (2021-2026)
  29. 4.5.4 Teriak Cyproheptadine Product Portfolio
  30. 4.5.5 Teriak Recent Developments
  31. 4.6 Royal Pharma
  32. 4.6.1 Royal Pharma Company Information
  33. 4.6.2 Royal Pharma Business Overview
  34. 4.6.3 Royal Pharma Cyproheptadine Sales, Revenue and Gross Margin (2021-2026)
  35. 4.6.4 Royal Pharma Cyproheptadine Product Portfolio
  36. 4.6.5 Royal Pharma Recent Developments
  37. 4.7 Qualipharm
  38. 4.7.1 Qualipharm Company Information
  39. 4.7.2 Qualipharm Business Overview
  40. 4.7.3 Qualipharm Cyproheptadine Sales, Revenue and Gross Margin (2021-2026)
  41. 4.7.4 Qualipharm Cyproheptadine Product Portfolio
  42. 4.7.5 Qualipharm Recent Developments
  43. 4.8 Pharma Arte
  44. 4.8.1 Pharma Arte Company Information
  45. 4.8.2 Pharma Arte Business Overview
  46. 4.8.3 Pharma Arte Cyproheptadine Sales, Revenue and Gross Margin (2021-2026)
  47. 4.8.4 Pharma Arte Cyproheptadine Product Portfolio
  48. 4.8.5 Pharma Arte Recent Developments
  49. 4.9 Panbiotic Laboratories
  50. 4.9.1 Panbiotic Laboratories Company Information
  51. 4.9.2 Panbiotic Laboratories Business Overview
  52. 4.9.3 Panbiotic Laboratories Cyproheptadine Sales, Revenue and Gross Margin (2021-2026)
  53. 4.9.4 Panbiotic Laboratories Cyproheptadine Product Portfolio
  54. 4.9.5 Panbiotic Laboratories Recent Developments
  55. 4.10 Nichi-Iko Pharmaceutical
  56. 4.10.1 Nichi-Iko Pharmaceutical Company Information
  57. 4.10.2 Nichi-Iko Pharmaceutical Business Overview
  58. 4.10.3 Nichi-Iko Pharmaceutical Cyproheptadine Sales, Revenue and Gross Margin (2021-2026)
  59. 4.10.4 Nichi-Iko Pharmaceutical Cyproheptadine Product Portfolio
  60. 4.10.5 Nichi-Iko Pharmaceutical Recent Developments
  61. 4.11 Medphano
  62. 4.11.1 Medphano Company Information
  63. 4.11.2 Medphano Business Overview
  64. 4.11.3 Medphano Cyproheptadine Sales, Revenue and Gross Margin (2021-2026)
  65. 4.11.4 Medphano Cyproheptadine Product Portfolio
  66. 4.11.5 Medphano Recent Developments
  67. 4.12 Laboratoires Servier
  68. 4.12.1 Laboratoires Servier Company Information
  69. 4.12.2 Laboratoires Servier Business Overview
  70. 4.12.3 Laboratoires Servier Cyproheptadine Sales, Revenue and Gross Margin (2021-2026)
  71. 4.12.4 Laboratoires Servier Cyproheptadine Product Portfolio
  72. 4.12.5 Laboratoires Servier Recent Developments
  73. 4.13 Kalbe
  74. 4.13.1 Kalbe Company Information
  75. 4.13.2 Kalbe Business Overview
  76. 4.13.3 Kalbe Cyproheptadine Sales, Revenue and Gross Margin (2021-2026)
  77. 4.13.4 Kalbe Cyproheptadine Product Portfolio
  78. 4.13.5 Kalbe Recent Developments
  79. 4.14 General Pharma
  80. 4.14.1 General Pharma Company Information
  81. 4.14.2 General Pharma Business Overview
  82. 4.14.3 General Pharma Cyproheptadine Sales, Revenue and Gross Margin (2021-2026)
  83. 4.14.4 General Pharma Cyproheptadine Product Portfolio
  84. 4.14.5 General Pharma Recent Developments
  85. 4.15 Fu Yuan Pharmaceutical
  86. 4.15.1 Fu Yuan Pharmaceutical Company Information
  87. 4.15.2 Fu Yuan Pharmaceutical Business Overview
  88. 4.15.3 Fu Yuan Pharmaceutical Cyproheptadine Sales, Revenue and Gross Margin (2021-2026)
  89. 4.15.4 Fu Yuan Pharmaceutical Cyproheptadine Product Portfolio
  90. 4.15.5 Fu Yuan Pharmaceutical Recent Developments
  91. 4.16 Faes Pharma
  92. 4.16.1 Faes Pharma Company Information
  93. 4.16.2 Faes Pharma Business Overview
  94. 4.16.3 Faes Pharma Cyproheptadine Sales, Revenue and Gross Margin (2021-2026)
  95. 4.16.4 Faes Pharma Cyproheptadine Product Portfolio
  96. 4.16.5 Faes Pharma Recent Developments
  97. 4.17 Cipla Medpro South Africa
  98. 4.17.1 Cipla Medpro South Africa Company Information
  99. 4.17.2 Cipla Medpro South Africa Business Overview
  100. 4.17.3 Cipla Medpro South Africa Cyproheptadine Sales, Revenue and Gross Margin (2021-2026)
  101. 4.17.4 Cipla Medpro South Africa Cyproheptadine Product Portfolio
  102. 4.17.5 Cipla Medpro South Africa Recent Developments
  103. 4.18 Caillon and Hamonet
  104. 4.18.1 Caillon and Hamonet Company Information
  105. 4.18.2 Caillon and Hamonet Business Overview
  106. 4.18.3 Caillon and Hamonet Cyproheptadine Sales, Revenue and Gross Margin (2021-2026)
  107. 4.18.4 Caillon and Hamonet Cyproheptadine Product Portfolio
  108. 4.18.5 Caillon and Hamonet Recent Developments
  109. 4.19 Arena Pharmaceuticals
  110. 4.19.1 Arena Pharmaceuticals Company Information
  111. 4.19.2 Arena Pharmaceuticals Business Overview
  112. 4.19.3 Arena Pharmaceuticals Cyproheptadine Sales, Revenue and Gross Margin (2021-2026)
  113. 4.19.4 Arena Pharmaceuticals Cyproheptadine Product Portfolio
  114. 4.19.5 Arena Pharmaceuticals Recent Developments
  115. 4.20 Apex Pharma
  116. 4.20.1 Apex Pharma Company Information
  117. 4.20.2 Apex Pharma Business Overview
  118. 4.20.3 Apex Pharma Cyproheptadine Sales, Revenue and Gross Margin (2021-2026)
  119. 4.20.4 Apex Pharma Cyproheptadine Product Portfolio
  120. 4.20.5 Apex Pharma Recent Developments
  121. 4.21 Allena Pharmaceuticals
  122. 4.21.1 Allena Pharmaceuticals Company Information
  123. 4.21.2 Allena Pharmaceuticals Business Overview
  124. 4.21.3 Allena Pharmaceuticals Cyproheptadine Sales, Revenue and Gross Margin (2021-2026)
  125. 4.21.4 Allena Pharmaceuticals Cyproheptadine Product Portfolio
  126. 4.21.5 Allena Pharmaceuticals Recent Developments
  127. 4.22 Aero-Chem
  128. 4.22.1 Aero-Chem Company Information
  129. 4.22.2 Aero-Chem Business Overview
  130. 4.22.3 Aero-Chem Cyproheptadine Sales, Revenue and Gross Margin (2021-2026)
  131. 4.22.4 Aero-Chem Cyproheptadine Product Portfolio
  132. 4.22.5 Aero-Chem Recent Developments
5 Global Cyproheptadine Market Scenario by Region
  1. 5.1 Global Cyproheptadine Market Size by Region: 2021 VS 2025 VS 2032
  2. 5.2 Global Cyproheptadine Sales by Region: 2021-2032
  3. 5.2.1 Global Cyproheptadine Sales by Region: 2021-2026
  4. 5.2.2 Global Cyproheptadine Sales by Region: 2027-2032
  5. 5.3 Global Cyproheptadine Revenue by Region: 2021-2032
  6. 5.3.1 Global Cyproheptadine Revenue by Region: 2021-2026
  7. 5.3.2 Global Cyproheptadine Revenue by Region: 2027-2032
  8. 5.4 North America Cyproheptadine Market Facts & Figures by Country
  9. 5.4.1 North America Cyproheptadine Market Size by Country: 2021 VS 2025 VS 2032
  10. 5.4.2 North America Cyproheptadine Sales by Country (2021-2032)
  11. 5.4.3 North America Cyproheptadine Revenue by Country (2021-2032)
  12. 5.4.4 United States
  13. 5.4.5 Canada
  14. 5.5 Europe Cyproheptadine Market Facts & Figures by Country
  15. 5.5.1 Europe Cyproheptadine Market Size by Country: 2021 VS 2025 VS 2032
  16. 5.5.2 Europe Cyproheptadine Sales by Country (2021-2032)
  17. 5.5.3 Europe Cyproheptadine Revenue by Country (2021-2032)
  18. 5.5.4 Germany
  19. 5.5.5 France
  20. 5.5.6 U.K.
  21. 5.5.7 Italy
  22. 5.5.8 Netherlands
  23. 5.6 Asia Pacific Cyproheptadine Market Facts & Figures by Country
  24. 5.6.1 Asia Pacific Cyproheptadine Market Size by Country: 2021 VS 2025 VS 2032
  25. 5.6.2 Asia Pacific Cyproheptadine Sales by Country (2021-2032)
  26. 5.6.3 Asia Pacific Cyproheptadine Revenue by Country (2021-2032)
  27. 5.6.4 China
  28. 5.6.5 Japan
  29. 5.6.6 South Korea
  30. 5.6.7 India
  31. 5.6.8 Australia
  32. 5.6.9 China Taiwan
  33. 5.6.10 Southeast Asia
  34. 5.7 South America Cyproheptadine Market Facts & Figures by Country
  35. 5.7.1 South America Cyproheptadine Market Size by Country: 2021 VS 2025 VS 2032
  36. 5.7.2 South America Cyproheptadine Sales by Country (2021-2032)
  37. 5.7.3 South America Cyproheptadine Revenue by Country (2021-2032)
  38. 5.7.4 Mexico
  39. 5.7.5 Brazil
  40. 5.7.6 Argentina
  41. 5.8 Middle East and Africa Cyproheptadine Market Facts & Figures by Country
  42. 5.8.1 Middle East and Africa Cyproheptadine Market Size by Country: 2021 VS 2025 VS 2032
  43. 5.8.2 Middle East and Africa Cyproheptadine Sales by Country (2021-2032)
  44. 5.8.3 Middle East and Africa Cyproheptadine Revenue by Country (2021-2032)
  45. 5.8.4 Turkey
  46. 5.8.5 Saudi Arabia
  47. 5.8.6 UAE
6 Segment by Type
  1. 6.1 Global Cyproheptadine Sales by Type (2021-2032)
  2. 6.1.1 Global Cyproheptadine Sales by Type (2021-2032) & (K Units)
  3. 6.1.2 Global Cyproheptadine Sales Market Share by Type (2021-2032)
  4. 6.2 Global Cyproheptadine Revenue by Type (2021-2032)
  5. 6.2.1 Global Cyproheptadine Sales by Type (2021-2032) & (US$ Million)
  6. 6.2.2 Global Cyproheptadine Revenue Market Share by Type (2021-2032)
  7. 6.3 Global Cyproheptadine Price by Type (2021-2032)
7 Segment by Application
  1. 7.1 Global Cyproheptadine Sales by Application (2021-2032)
  2. 7.1.1 Global Cyproheptadine Sales by Application (2021-2032) & (K Units)
  3. 7.1.2 Global Cyproheptadine Sales Market Share by Application (2021-2032)
  4. 7.2 Global Cyproheptadine Revenue by Application (2021-2032)
  5. 7.2.1 Global Cyproheptadine Sales by Application (2021-2032) & (US$ Million)
  6. 7.2.2 Global Cyproheptadine Revenue Market Share by Application (2021-2032)
  7. 7.3 Global Cyproheptadine Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
  1. 8.1 Cyproheptadine Value Chain Analysis
  2. 8.1.1 Cyproheptadine Key Raw Materials
  3. 8.1.2 Raw Materials Key Suppliers
  4. 8.1.3 Cyproheptadine Production Mode & Process
  5. 8.2 Cyproheptadine Sales Channels Analysis
  6. 8.2.1 Direct Comparison with Distribution Share
  7. 8.2.2 Cyproheptadine Distributors
  8. 8.2.3 Cyproheptadine Customers
9 Global Cyproheptadine Analyzing Market Dynamics
  1. 9.1 Cyproheptadine Industry Trends
  2. 9.2 Cyproheptadine Industry Drivers
  3. 9.3 Cyproheptadine Industry Opportunities and Challenges
  4. 9.4 Cyproheptadine Industry Restraints
10 Report Conclusion
    11 Disclaimer

      GET THE RESEARCH

      Choose your license.

      Choose who needs access.
      All options are for this report and research series.

      Compare access permissions.

      Single User License
      One named user. Individual access.
      Multi User License
      Up to 5 users in the same department.
      Enterprise License
      Organization-wide access within the agreed license.

      Access applies to the purchased edition. Later editions are separate purchases.

      License options
      $2,950USD
      Buy now

      PDF by email within 3–5 working days after payment confirmation.

      Talk to an analyst
      APO Research, Inc.
      Talk to an analyst